Join Growin Stock Community!

商之器8409.TW Overview

TW StockBiotech. & Medical
(No presentation for 8409)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

商之器（8409）Overall Performance

商之器（8409）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

商之器（8409） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

商之器（8409）Key Information

商之器（8409）Profile

EBM Technologies Incorporated engages in the development and marketing of software and integrity solutions to the health sector in Taiwan and internationally. The company offers Enterprise PACS (picture archiving and communication systems) solutions, including SoliPACS that unites various products of the radiology, mammography, and dental fields; SoliPACS Gateway, a DICOM gateway; SoliPACS Server, an interface between HIS and RIS patient data and PACS; SoliPACS Web Viewer, which enables radiologists and physicians to view, compare, utilize, and select DICOM-compliant images; SoliPACS Report, offers a tool for generating customized reports; and Advanced Server Archive, a PACS storage system. It also provides UDE (Ubiquitous Diagnostic Environment) App, which converts standard iPad Pro into a standalone DICOM server, viewer, display, and Al all in one; MobiPACS Server to store, process, and retrieve image files for mobile devices; MobiPACS App, an in mobile medical image viewing app; MobiPACS Web Viewer for viewing images from Internet-enabled end devices; MobiPACS Share, a cloud-based platform; and MobiPACS Multi, supports doctors to connect various iPads/iPad Pros for image display. In addition, the company offers Vital-Sign On-the-Go, a patient monitoring solution; Rad@, for viewing medical-grade images and diagnose; Digital Pathology Scanner, transforms physical slides to whole side images; AgileRIS App, an offline reporting solution; EPS Pi, a viewer ready DICOM device; and UniGate_i (UGI) App. Further, it provides Telemed, which interlinks medical facilities; Electronic Medical Record, a digital version of the paper-based individual medical record for patients' medical history; Personal Health Record, offers electronic access to the individual's medical history; and eHealth solutions for retrieving and reviewing patient images, vital sign data, and ECG waveforms. The company was founded in 1988 and is headquartered in Taipei, Taiwan.

商之器（8409）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
60.57%
Net Margin
13.26%
Revenue Growth (YoY)
73.98%
Profit Growth (YoY)
39.91%
3-Year Revenue Growth
42.07%
3-Year Profit Growth
34.42%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
60.57%
Net Margin
13.26%
Revenue Growth (YoY)
73.98%
Profit Growth (YoY)
39.91%
3-Year Revenue Growth
42.07%
3-Year Profit Growth
34.42%
default symbol

8409

商之器

20.40D

-2.21%

(-0.02)

  • When is 8409's latest earnings report released?

    The most recent financial report for 商之器 (8409) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 8409's short-term business performance and financial health. For the latest updates on 8409's earnings releases, visit this page regularly.

  • Where does 8409 fall in the P/E River chart?

    According to historical valuation range analysis, 商之器 (8409)'s current price-to-earnings (P/E) ratio is 13.91, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 8409?

    According to the latest financial report, 商之器 (8409) reported an Operating Profit of 25.67M with an Operating Margin of 22.59% this period, representing a growth of 316.28% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 8409's revenue growth?

    In the latest financial report, 商之器 (8409) announced revenue of 113.65M, with a Year-Over-Year growth rate of 135.7%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 8409 have?

    At the end of the period, 商之器 (8409) held Total Cash and Cash Equivalents of 134.78M, accounting for 0.31 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 8409 go with three margins increasing?

    In the latest report, 商之器 (8409) achieved the “three margins increasing” benchmark, with a gross margin of 60.46%%, operating margin of 22.59%%, and net margin of 23.21%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 8409's profit trajectory and future growth potential.

  • Is 8409's EPS continuing to grow?

    According to the past four quarterly reports, 商之器 (8409)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.82. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 8409?

    商之器 (8409)'s Free Cash Flow (FCF) for the period is 457K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 87.32% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.